v3.25.3

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 77,344	$ 64,696
Marketable securities	251,965	390,025
Prepaid expenses and other current assets	6,829	7,634
Total current assets	336,138	462,355
Property and equipment, net	561	873
Other assets	5,475	197
Operating lease right-of-use assets, net	789	1,243
Total assets	342,963	464,668
Current liabilities
Accounts payable	3,515	4,458
Accrued expenses and other current liabilities	15,828	13,345
Current portion of operating lease liabilities	832	800
Total current liabilities	20,175	18,603
Operating lease liabilities	213	842
Income taxes payable	6,795	6,356
Total liabilities	27,183	25,801
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 78,126,796 and 84,463,059 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	78	84
Additional paid-in capital	793,166	802,770
Accumulated other comprehensive gain	238	233
Accumulated deficit	(477,702)	(364,220)
Total stockholders’ equity	315,780	438,867
Total liabilities and stockholders’ equity	$ 342,963	$ 464,668

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Atea Pharmaceuticals, Inc. 10-Q